WO2009149166A3 - Methods and compositions for the diagnosis and treatment of proliferative disorders - Google Patents
Methods and compositions for the diagnosis and treatment of proliferative disorders Download PDFInfo
- Publication number
- WO2009149166A3 WO2009149166A3 PCT/US2009/046103 US2009046103W WO2009149166A3 WO 2009149166 A3 WO2009149166 A3 WO 2009149166A3 US 2009046103 W US2009046103 W US 2009046103W WO 2009149166 A3 WO2009149166 A3 WO 2009149166A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- present
- expression
- treatment
- markers
- mpnst
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention identifies expression markers associated with neurofibromatosis 1 (NF1) by examining gene expression in tissue from lesions from neurofibromas, plexiform neurofibromas and malignant peripheral nerve sheath tumors (MPNST). The present invention also provides for diagnostic markers as well as markers that can be used to monitor disease states, disease progression, drug toxicity, drug efficacy and drug metabolism. The present invention relates to novel, rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that act as a therapeutic agent for the treatment of a proliferative disorder. In another aspect, the present invention provides a method of treating a patient with neurofibromatosis and/or MPNST, comprising administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene related to the NF1-Ras pathway.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5842808P | 2008-06-03 | 2008-06-03 | |
US61/058,428 | 2008-06-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009149166A2 WO2009149166A2 (en) | 2009-12-10 |
WO2009149166A3 true WO2009149166A3 (en) | 2010-01-28 |
Family
ID=41398837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/046103 WO2009149166A2 (en) | 2008-06-03 | 2009-06-03 | Methods and compositions for the diagnosis and treatment of proliferative disorders |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009149166A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7858323B2 (en) | 2004-06-09 | 2010-12-28 | The Regents Of The University Of Michigan | Phage microarray profiling of the humoral response to disease |
WO2011116209A2 (en) * | 2010-03-17 | 2011-09-22 | The Regents Of The University Of Michigan | Using phage epitopes to profile the immune response |
WO2012015765A2 (en) | 2010-07-27 | 2012-02-02 | Genomic Health, Inc. | Method for using gene expression to determine prognosis of prostate cancer |
CN103045741B (en) * | 2012-12-26 | 2014-07-02 | 首都医科大学宣武医院 | Kit for diagnosing cerebrovascular stenosis and application thereof |
CN104372081B (en) * | 2014-10-29 | 2016-08-17 | 华南农业大学 | The LAMP detection primer of one group of Eggs of Silkworm microsporidian and kit |
CN110846343B (en) * | 2019-11-09 | 2020-12-01 | 河南理工大学 | Preparation and purification method of recombinant adenovirus expressing Sox4 gene |
WO2022087023A1 (en) * | 2020-10-19 | 2022-04-28 | Baruch S. Blumberg Institute | Methods and kits for diagnosing and treating cancers |
KR102706327B1 (en) * | 2021-03-24 | 2024-09-13 | 재단법인 아산사회복지재단 | Composition for Differential Diagnosis of Malignant Peripheral Nerve Sheath Tumor |
US20240175872A1 (en) * | 2021-03-24 | 2024-05-30 | The Asan Foundation | Composition for differential diagnosis of malignant peripheral nerve sheath tumor |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040091927A1 (en) * | 2000-06-27 | 2004-05-13 | Lan Kluwe | Method for the determination of data for the preparation of the diagnosis of phakomatosis |
-
2009
- 2009-06-03 WO PCT/US2009/046103 patent/WO2009149166A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040091927A1 (en) * | 2000-06-27 | 2004-05-13 | Lan Kluwe | Method for the determination of data for the preparation of the diagnosis of phakomatosis |
Non-Patent Citations (8)
Title |
---|
FATHALLAH-SHAYKH ET AL.: "Genomic expression discovery predicts pathways and opposing functions behind phenotypes.", J. BIOL. CHEM., vol. 278, no. 26, 27 June 2003 (2003-06-27), pages 23830 - 23833 * |
GUTMANN ET AL.: "Comparative gene expression profile analysis of neurofibromatosis 1- associated and sporadic pilocytic astrocytomas.", CANCER RES., vol. 62, no. 7, 1 April 2002 (2002-04-01), pages 2085 - 2091 * |
KIM ET AL.: "Analysis of mammalian septin expression in human malignant brain tumors.", NEOPLASIA, vol. 6, no. 2, March 2004 (2004-03-01), pages 168 - 178 * |
LEE ET AL.: "Transcriptional profiling in an MPNST-derived cell line and normal human Schwann cells.", NEURON. GLIA. BIOL., vol. 1, no. 2, May 2004 (2004-05-01), pages 135 - 147 * |
LEVY ET AL.: "Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1.", CLIN. CANCER RES., vol. 13, no. 2, P.1, 15 January 2007 (2007-01-15), pages 398 - 407 * |
RUSSELL ET AL.: "Do septins have a role in cancer?", BR. J. CANCER., vol. 93, no. 5, 5 September 2005 (2005-09-05), pages 499 - 503 * |
TANG ET AL.: "Blood gene expression profiling of neurologic diseases: a pilot microarray study.", ARCH. NEUROL., vol. 62, no. 2, February 2005 (2005-02-01), pages 210 - 215 * |
TANG ET AL.: "Human blood genomics: distinct profiles for gender, age and neurofibromatosis type 1.", BRAIN RES. MOL. BRAIN RES., vol. 132, no. 2, 20 December 2004 (2004-12-20), pages 155 - 167 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009149166A2 (en) | 2009-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009149166A3 (en) | Methods and compositions for the diagnosis and treatment of proliferative disorders | |
US20220016059A1 (en) | Methods for the treatment of bladder cancer | |
Heist et al. | Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer | |
Stubblefield et al. | Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study | |
MX2009002921A (en) | Azetidinone derivatives for the treatment of disorders of the lipid metabolism. | |
WO2003082078A3 (en) | Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles | |
EP3795141A1 (en) | Solid solution compositions | |
MX2009002924A (en) | Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders. | |
EP2985281A3 (en) | Isoindoline compounds for use in the treatment of cancer | |
TW200740452A (en) | Therapeutic gastrodia extracts | |
Delorme et al. | Treatment of Neuropathic Pain with 5% Lidocaine‐Medicated Plaster: Five Years of Clinical Experience | |
TW200736252A (en) | Novel heteroaryl substituted benzothiazoles | |
WO2011066521A3 (en) | Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same | |
EP2862572B1 (en) | Prophylactic and/or therapeutic agent for mild cognitive impairment | |
MA30720B1 (en) | ANALOGUES OF 2-PHENOXYPYRIMIDINONE | |
Mischoulon et al. | An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding | |
Yildirim et al. | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality | |
Ilhan et al. | Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease | |
WO2010051196A8 (en) | Novel substituted azabenzoxazoles | |
Mao et al. | Characteristics and outcomes of primary central nervous system lymphoma: a retrospective study of 91 cases in a Chinese population | |
Takei et al. | Management of cancer pain due to bone metastasis | |
BRPI0415215A (en) | application of a polyphenol for the treatment of a cancerous or precancerous skin lesion | |
KR102232198B1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
KR101901001B1 (en) | A Pharmaceutical composition comprising PPAR-β inhibitor for enhancing Anti-cancer effect | |
WO2009089066A3 (en) | Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09759325 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09759325 Country of ref document: EP Kind code of ref document: A2 |